Skip to main content
SpringerLink
Log in

Phase II study of acivicin as a 72-hr continuous infusion in patients with untreated colorectal cancer. A National Cancer Institute of Canada clinical trials group study

  • Clinical Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

The National Cancer Institute of Canada (NCIC) Clinical Trials Group has carried out a phase II study of acivicin given as a 72-hour continuous infusion in previously untreated patients with measurable metastatic colorectal carcinoma. Toxicity in 24 patients was mild to moderate and consisted primarily of GI symptoms such as nausea, vomiting, diarrhea or CNS changes including drowsiness, lethargy, dizziness. No responses were seen in 23 evaluable patients. We did not find acivicin given as described to be effective in colorectal carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Houchens DP, Ovejera AA, Sheridan MA, Johnson RK, Bogden AE, Neil GL: Therapy for mouse tumors and human tumor xenografts with the antitumor antibiotic AT-125. Cancer Treat Rep 63:473–476, 1979

    Google Scholar 

  2. O'Dwyer PJ, Alonso MT, Leyland-Jones B: Acivicin: A new glutamine antagonist in clinical trials. J Clin Oncol 2:1064–1071, 1984

    Google Scholar 

  3. Earhart RH, Koeller JM, Davis TE, Borden EC, McGovren JP, Davis HL, Tormey DC: Phase I trial and pharmacokinetics of acivicin administered by 72-hour infusion. Cancer Treat Rep 67:683–692, 1983

    Google Scholar 

  4. Weiss GR, McGovren JP, Schade D, Kufe DW: Phase I and pharmacological study of acivicin by 24-hour continuous infusion. Cancer Res 42:3892–3895, 1982

    Google Scholar 

  5. Sridhar KS, Ohnuma T, Chahinian AP, Holland JF: Phase I study of acivicin in patients with advanced cancer. Cancer Treat Rep 67: 701–703, 1983

    Google Scholar 

  6. Maroun JA, Fields AL, Pater JL, Stewart DM, Cripps C, Eisenhauer E: Phase II study of acivicin in colorectal carcinoma. A National Cancer Institute of Canada Study. Cancer Treat Rep 68:1121–1123, 1984

    Google Scholar 

  7. Etheridge B, Vonhoff D: Activity of one hour and continuous exposure of acivicin in a human tumor cloning system. Proc Amer Soc Clin Oncol (Abstr) 4:30, 1985

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. NCIC Clinical Trials Group, Queen's University, Kingston, Ontario, Canada

    Elizabeth A. Eisenhauer (Director)

  2. Ottawa Regional Cancer Center, Ottawa, Ontario, Canada

    Jean A. Maroun

  3. Cross Cancer Institute, Edmonton, Albert, Canada

    Anthony L. Fields

  4. Algoma District Medical Group, Sault Ste. Marie, Ontario, Canada

    Paul L. D. Walde

Authors
  1. Elizabeth A. Eisenhauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean A. Maroun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anthony L. Fields
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paul L. D. Walde
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eisenhauer, E.A., Maroun, J.A., Fields, A.L. et al. Phase II study of acivicin as a 72-hr continuous infusion in patients with untreated colorectal cancer. A National Cancer Institute of Canada clinical trials group study. Invest New Drugs 5, 375–378 (1987). https://doi.org/10.1007/BF00169978

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00169978

Key words

Search

Navigation